Business
Eisai to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, Denmark, and online. The lecanemab data and additional resea
About this update from Eisai Co., Ltd.
[{"type":"text","content":"TOKYO, March 10, 2026 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today the company will present the latest findings on lecanemab (generic name, U.S. brand name: LEQEMBI®), Eisai's anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer's disease (AD), at the 20th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) from March 17-21, in Copenhagen, Denmark, and online. The lecanemab data and additional research findings from Eisai's AD portfolio will be featured in six presentations, including three oral presentations. Eisai will host an industry-sponsored symposium.","length":730,"tagName":"p"},{"type":"image","alt":"Eisai logo (PRNewsfoto/Eisai Inc.)","displaySize":"","headline":null,"caption":"Eisai logo (PRNewsfoto/Eisai Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":240,"url":"https://media.zenfs.com/en/prnewswire.com/3579c50e062a9bea3b8315d3f4b7fe57"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/bC1QM2fItt9ayq5d1qRr0Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQyMztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/3579c50e062a9bea3b8315d3f4b7fe57","width":400,"height":240}},"href":"https://mma.prnewswire.com/media/2348748/Eisai_logo_svg_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Oral and Poster PresentationsOral presentations will include the latest findings from a United States (U.S.) real-world long-term treatment persistence study, and efficacy and safety outcomes in apolipoprotein E ε4 (ApoEε4) homozygous carriers in a U.S. multicenter real-world study. In addition, four-year data from the Clarity AD Open-Label Extension trial in ApoEε4 non-carriers and heterozygotes, and a genome-wide association study on novel genetic variants associated with cognitive decline in AD will be presented as posters.","length":538,"tagName":"p"},{"type":"text","content":"Eisai Symposium – Continue Life Their Way: Early Intervention in Alzheimer's DiseaseEisai is sponsoring a symposium featuring four leading global experts in the field of AD, on the topics of why early intervention matters, continuing early AD treatment and real-world outcomes. The symposium aims to enhance understanding of the value...